Response: Although we acknowledge the applicant's concerns regarding the descriptor for C1739, we do not agree that the device category code should be withdrawn and replaced with a new code effective January 1, 2026, for the following reasons: First, per the applicant's request prior to CY 2026 rulemaking, CMS revised the descriptor for C1739 to read, effective October 1, 2025: Tissue marker, uniquely detectable and identifiable with probe/sensor, any method (implantable), with delivery system
These settings provide a sense of community, understanding, and support, which can be invaluable during the withdrawal process
Accessible and Affordable Wellness REVIV makes Vitamin B12 shots and IV therapies containing B12 accessible and affordable, without compromising on quality
Up to 17.5% of autopsies of individuals who never had TN reveal vascular contact without significant neurovascular compression.16 Imaging techniques are able to identify significant neurovascular compression17 and differentiate it from simple contact, enabling better selection of surgical candidates, with classical series reporting no improvement after microvascular decompression in up to 30% of patients undergoing the procedure.18 Secondary trigeminal neuralgia Secondary TN presents with recurrent paroxysms of unilateral facial pain meeting the diagnostic criteria for TN, either purely paroxysmal or associated with concomitant continuous or near-continuous pain, in patients with a documented underlying disease recognised as a cause of the neuralgia, which would explain the pain
Meningitis Meningitis is a serious infection that causes inflammation of the protective membranes around the brain and spinal cord, requiring urgent medical attention
